Latest Ratios: P/E Ratio -8.7x · EV/EBITDA N/A · ROE -45.7%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.1B | $2.9B | $3.4B | $2.9B | $3.5B | $5.4B | $9.4B | $1.7B | $1.9B | $234M | — |
| Enterprise Value | $3.9B | $2.7B | $3.2B | $2.9B | $3.3B | $5.2B | $9.0B | $1.7B | $1.8B | $16M | — |
| P/E Ratio → | -8.70 | — | — | — | — | — | 132.95 | — | — | — | — |
| P/S Ratio | — | — | — | 8.92 | 32.19 | 111.38 | 28.12 | 62.43 | 14.82 | — | — |
| P/B Ratio | 4.47 | 2.86 | 2.73 | 2.86 | 3.35 | 5.63 | 8.20 | 4.22 | 3.50 | 0.50 | — |
| P/FCF | — | — | — | — | — | — | 22.85 | — | 40.96 | — | — |
| P/OCF | — | — | — | — | — | — | 22.68 | — | 38.18 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 8.69 | 30.73 | 106.67 | 26.82 | 62.17 | 14.22 | — | — |
| EV / EBITDA | — | — | — | — | — | — | 126.34 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | 143.53 | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 21.79 | — | 39.30 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating Margin | — | — | — | -59.5% | -314.2% | -607.8% | 18.7% | -799.1% | -35.9% | — | — |
| Net Profit Margin | — | — | — | -43.9% | -300.6% | -597.2% | 21.2% | -740.7% | -28.1% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -45.7% | -45.7% | -37.4% | -14.0% | -32.5% | -27.5% | 9.2% | -42.0% | -7.2% | -24.5% | -72.5% |
| ROA | -40.7% | -40.7% | -33.4% | -11.1% | -22.8% | -19.3% | 6.6% | -32.5% | -6.3% | -23.3% | -56.3% |
| ROIC | -42.6% | -42.6% | -35.5% | -16.0% | -31.6% | -30.7% | 8.6% | -37.3% | -9.7% | -29.3% | -77.9% |
| ROCE | -47.9% | -47.9% | -41.5% | -18.1% | -32.1% | -23.1% | 6.1% | -37.5% | -8.4% | -24.5% | -59.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 | 0.06 | 0.18 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | 0.97 | — | — | — | — |
| Net Debt / Equity | — | -0.16 | -0.10 | -0.07 | -0.15 | -0.24 | -0.38 | -0.02 | -0.14 | -0.47 | -0.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | -6.15 | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -1.06 | — | -1.65 | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -46.11 | — |
Net cash position: cash ($205M) exceeds total debt ($42M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.16 | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 | 20.86 | 9.48 | 14.67 | 28.92 | 19.98 |
| Quick Ratio | 9.16 | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 | 20.86 | 9.48 | 14.93 | 28.95 | 19.98 |
| Cash Ratio | 8.82 | 8.82 | 8.14 | 13.27 | 3.67 | 2.29 | 20.50 | 9.16 | 14.16 | 28.68 | 19.58 |
| Asset Turnover | — | — | — | 0.29 | 0.07 | 0.03 | 0.21 | 0.05 | 0.20 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 3.78 | 31.24 | 9.20 | — | — | 24.15 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | 0.8% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 4.4% | — | 2.4% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $175M | $164M | $137M | $126M | $122M | $113M | $96M | $93M | $15M | $6M |
Clinical milestone funding dependency
According to market data, Denali trades at a price-to-book ratio of 4.43, which suggests investors are pricing in the long-term potential of the proprietary Transport Vehicle platform rather than the company's current lack of commercial revenue or meaningful earnings multiples.
The absence of positive P/E or EV/EBITDA metrics reflects the company's pre-commercial status, where valuation is driven by speculative probability-of-success models for its CNS pipeline. Investors should monitor whether this platform premium remains sustainable if clinical readouts fail to demonstrate clear superiority over existing standard-of-care therapies.
As reported in financial statements, Denali's ROIC has trended negatively, reaching -14.4% in 2026Q1, which highlights the ongoing destruction of invested capital as the company prioritizes high-cost clinical trial execution over immediate returns on its research-heavy asset base.
The consistent negative return profile is a structural feature of a biotech firm in the development phase, where capital is consumed to build intellectual property rather than generate operating income. This trend warrants further investigation into whether the company can achieve a positive inflection point before its current cash reserves are fully exhausted.
Based on Denali's reported figures, the current ratio has compressed from 13.65 in 2023Q4 to 9.28 in 2026Q1, indicating that while the company maintains a high level of short-term assets, its liquidity position is steadily eroding under the weight of sustained operational cash burn.
The high current ratio is somewhat misleading, as it is heavily influenced by the timing of milestone payments rather than operational efficiency. Investors should monitor the rate of cash depletion, as the current trajectory suggests that the company may face a liquidity crunch if clinical milestones are delayed.
As indicated by peer comparison data, Denali's P/B of 4.43 sits in the middle of the cohort, trailing high-valuation peers like Protagonist Therapeutics but significantly exceeding the depressed multiples of Arvinas, suggesting the market is selectively rewarding companies with perceived platform scalability.
The wide variance in peer multiples suggests that the market is not valuing these companies as a homogenous group, but rather as individual bets on specific delivery technologies. Denali's position appears to be a function of its partnership-heavy model, which provides a degree of validation that pure-play research firms may lack.
The most commonly misapplied metric for Denali is the P/B ratio, which obscures the fact that the company's book value is largely composed of cash and intangible assets that may hold little liquidation value in the event of clinical failure.
Analysts should instead focus on the 'Cash Burn from Operations' relative to the remaining cash runway, as this provides a more accurate assessment of the company's survival horizon. Relying on traditional balance sheet ratios like P/B fails to account for the binary nature of the company's primary assets, which are its clinical programs.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DNLI stock.
Denali Therapeutics Inc.'s current P/E ratio is -8.7x. The historical average is 133.0x.
Denali Therapeutics Inc.'s return on equity (ROE) is -45.7%. The historical average is -29.4%.
Based on historical data, Denali Therapeutics Inc. is trading at a P/E of -8.7x. Compare with industry peers and growth rates for a complete picture.